Published in final edited form as:

J Cancer Surviv. 2017 February ; 11(1): 1–12. doi:10.1007/s11764-016-0556-1.

Long-Term functional outcomes and quality of life in adult survivors of childhood extremity sarcomas: a report from the St. Jude Lifetime Cohort Study

I Fernandez-Pineda, MD¹, MM Hudson, MD², AS Pappo, MD², MW Bishop, MD², JL Klosky, PhD³, TM Brinkman, PhD⁵, DK Srivastava, PhD⁴, MD Neel, MD¹, BN Rao, MD¹, AM Davidoff, MD¹, KR Krull, PhD⁵, DA Mulrooney, MD², LL Robison, PhD⁵, and KK Ness, PhD⁵

¹Department of Surgery, St. Jude Children's Research Hospital, 226 Danny Thomas Place, Memphis, Tennessee 38105

²Department of Oncology, St. Jude Children's Research Hospital, 226 Danny Thomas Place, Memphis, Tennessee 38105

³Department of Psychology, St. Jude Children's Research Hospital, 226 Danny Thomas Place, Memphis, Tennessee 38105

⁴Department of Biostatistics, St. Jude Children's Research Hospital, 226 Danny Thomas Place, Memphis, Tennessee 38105

⁵Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, 226 Danny Thomas Place, Memphis, Tennessee 38105

Abstract

PURPOSE—This study compared measured physical performance, health-related-quality-of-life (HRQOL), and social role attainment between extremity sarcoma survivors and controls, and evaluated associations between disease and treatment exposures, health conditions, and performance measures.

METHODS—Survivors of extremity sarcoma from the St. Jude Lifetime cohort, and controls frequency matched by age-, sex-, and race completed physical performance testing and questionnaires. Survivors with Z-scores on outcome measures -2.0 SD (compared to controls) were categorized with severe impairment/limitation.

RESULTS—Among 206 survivors (52.4% male median age 36 (range 19–65) years, 37% had low relative lean mass, 9.7% an ejection fraction $<50\%$, 51.5% diffusion capacity for carbon

Corresponding Author: Israel Fernandez Pineda, MD, St. Jude Children's Research Hospital, 226 Danny Thomas Place, MS133, Memphis, Tennessee 38105, Telephone: 901-595-2315, Facsimile: 901-595-2207, israel.fernandez-pineda@stjude.org.

Conflict of Interest Declaration: The authors declare no competing financial interests.

Compliance with Ethical Standards:

Conflict of Interest: The authors declare no competing financial interests.

Ethical approval: No animals were involved.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent: Informed consent was obtained from all individual participants included in the study.

monoxide <75%, 27.7% sensory and 25.2% motor neuropathy, and 78.2% musculoskeletal complications. Severe impairments/limitations were present among 25% of survivors on fitness, balance, and physical HRQOL measures, and among 15% on strength and activity of daily living measures. Lower extremity tumor location (OR 8.23, 95% CI 2.54–26.67, P-value 0.0004) and amputation (OR 8.07, 95% CI 3.06–21.27, P-value <0.0001) were associated with poor fitness. Poor fitness was associated with increased odds of scoring <40 on the SF-36 physical component summary (OR 4.83, 95% CI 1.95–11.99, P-value 0.001) and role-physical subscale (OR 3.34, 95% CI 1.33–8.43, P-value 0.01). Survivors and controls had similar rates of marriage, independent living, employment and college attendance.

CONCLUSIONS—Extremity sarcoma survivors experience high rates of physical impairment, and report lower than expected physical HRQOL. However, they are as likely as peers to be married, live independently, be employed, and attend college.

IMPLICATIONS FOR SURVIVORS—Follow-up for extremity sarcoma survivors should include assessment of need for further orthopedic care and rehabilitation to address cardiopulmonary and musculoskeletal health.

Keywords

musculoskeletal sarcoma; survivor; function; physical performance; quality of life; social role attainment

INTRODUCTION

Musculoskeletal sarcomas in children and adolescents are a group of rare malignant tumors involving bone and soft tissue, accounting for 4–13% of all malignant neoplasms in these age groups. Survival has improved over the last decades due to advances in treatment, including adjuvant chemotherapy [1,2]. Estimates indicate there are nearly 50,000 survivors of pediatric bone and soft tissue sarcoma in the United States; 36,723 are younger than age 50 years [3]. Because curative treatment requires a multimodal approach involving surgery, radiation, and chemotherapy, sarcoma survivors are at risk for therapy-related complications [4,5]. Medical late effects, including infertility, gonadal hormone deficiency, second malignant neoplasms, cardiomyopathy, pulmonary dysfunction and renal insufficiency have been documented [4,6–11]. Self-report data from the Childhood Cancer Survivor Study (CCSS) also indicate that adult survivors of childhood bone and soft tissue sarcoma are vulnerable to adverse physical performance outcomes that increase with age, and are associated with poor health-related-quality-of-life (HRQOL), lower educational attainment, and unemployment [12].

Previous studies provide insight regarding functional loss and broadly identify those at risk for a poor outcome. However, because this information is based on self-report, it does not provide details about physical performance needed to guide development of interventions tailored to this population. In addition, identification of disease specific and demographic variables, treatment modalities, medical complications, and lifestyle factors that influence physical performance would provide information for survivors currently receiving treatment to identify those in need of rehabilitation and follow-up.

The aims of this study were to 1) compare measured physical performance, HRQOL, and social attainment between survivors of childhood musculoskeletal sarcomas of the extremities to healthy controls, frequency matched by age-, sex-, and race, and 2) evaluate associations between disease and treatment variables, health conditions, and physical performance measures in this population.

MATERIAL AND METHODS

Study participants

Participants were members of the St. Jude Lifetime cohort (SJLIFE), treated for musculoskeletal sarcomas of the extremities during childhood, who completed physical performance assessments and questionnaires that included the Medical Outcomes Survey Short-Form 36 (SF-36) and items related to social role attainment. Sarcoma of the extremity was defined as a malignant tumor derived from mesenchymal bone or soft-tissue. Pelvic tumors were excluded. Eligibility criteria for inclusion in the SJLIFE cohort include: (1) diagnosis of childhood malignancy treated at St. Jude Children's Research Hospital (SJCRH); (2) survival of >10 years from diagnosis; and (3) current age ≥ 18 years. Three levels of participation are offered in the SJLIFE study: (1) comprehensive evaluation on the SJCRH campus; (2) limited local evaluation by Examination Management Services, Inc. (EMSI) for survivors who decline to return to SJCRH or (3) completion of health surveys by mail or phone interview for those survivors who decline to return to SJCRH or undergo a local evaluation [13,14]. Briefly, participants were at least ten-year survivors of childhood cancer, treated between 1962 and 2004, and 18 years of age or older. As of October 2013, this included 328 survivors of an extremity sarcoma, 206 (62.8%) of whom completed a functional assessment. A comparison group of adults without previous cancer diagnoses, recruited from among parents, friends and relatives of current St. Jude patients, and frequency matched by five year age group, sex, and race, completed the same assessments. Study documents were approved by the institutional review board. Participants provided written informed consent prior to assessment.

Variable definitions

Physical performance—Physical performance measures included flexibility, balance, muscle strength, general fitness, and overall physical performance. Results are presented as means and standard deviations (SD) and percentages to indicate the proportion of survivors whose scores were 1.5 and 2.0 SD below the means of age-, sex-, and race-matched peers. Low back and hamstring flexibility were assessed by having the participants complete the sit-and-reach test [15]. Ankle passive and active range of motion were measured in sitting with the hips and knees in 90 degrees of flexion with a goniometer [16,17]. Balance was evaluated with the Sensory Organization Test (Neurocom Smart Equitest, Natus Medical, Clackamas, OR). Participants maintained an upright posture during six sensory conditions while standing in a visual surround on a force plate that measured time spent inside a 12° sway envelope. Overall composite and vestibular scores (percentages) were used for analysis [18].

Hand grip strength was measured with a dynamometer (Jamar, Lafayette Instrument Company, Lafayette, IN) with the participant sitting, the shoulder in 0–10° of flexion/abduction, the elbow in 90° of flexion, and the forearm in neutral [19,20]. Isokinetic knee extension, dorsiflexion, and plantarflexion were assessed with an isokinetic dynamometer (Biodex System 3.0, Biodex Medical Systems, Shirley, NY). Measurements of peak torque (Newton-meters (Nm)) per kilogram (kg) of body weight were made at speeds of 60°, 180°, and 300° per second for the quadriceps, and 60° and 90° per second for ankle motions [21,22]. For bilateral measures, the average of the maximum value from each side was used for analysis. For those with amputation, the maximum value from the intact extremity was used.

Fitness was evaluated with the six-minute-walk test [23]. Participants wore a heart rate monitor and walked in a level corridor. Encouragement was given every minute, and heart rate recorded at rest, 2, 4, and 6 minutes, and 2 minutes after test completion. Distance in meters and physiologic cost index (maximum heart rate – resting heart rate)/gait speed) were calculated. Overall physical performance was evaluated with the 7-item physical performance test (PPT), [24] where a score of 28/28 indicates no deficit.

Health-related quality of life (HRQOL)

HRQOL was measured using the Medical Outcomes Survey 36-Item Short Form Health Survey (SF-36) [25]. This widely used generic health profile provides subscale scores for 8 domains of HRQOL: general health, role physical, physical function, bodily pain, vitality, mental health, social function, and role emotional, and mental and physical health composite scores. The SF-36 provides age- and sex-specific norms. T-scores ≥ 40 were classified as poor HRQOL.

Social role attainment

Social attainment was assessed using indicators of adult achievement including marital status, independent living, employment, and educational attainment.

Independent variables—Participant characteristics, age, sex, and race, were obtained by questionnaire. Diagnosis and treatment data were obtained from medical records by trained abstractors and included diagnosis, metastatic status, relapse status, age at diagnosis, length of follow-up, tumor location(s), chemotherapy exposures and doses, radiation exposures and doses and surgery for local control, metastatic disease, relapse, and complications. Musculoskeletal complications from diagnosis through follow-up were obtained from extensive review of medical records and images by a surgeon (IFP) and by interview and examination during medical and functional evaluations. Participants were also screened for body composition abnormalities, cardiac impairment, pulmonary dysfunction, and neuropathy. Those with age-, race-, and sex-specific relative lean muscle mass for height z-scores < -1.5 SD were classified with low lean mass, [26] those with ejection fraction (EF) $< 50\%$ with cardiac impairment, [27] those with diffusing capacity of the lungs for carbon monoxide (DLCO_{corr}) $< 75\%$ with abnormal pulmonary function [28] and those with Common Terminology Criteria for Adverse Events (CTCAE) grades 2–4 peripheral sensory or motor dysfunction with neuropathy [29].

Statistical Analyses

Means for demographic and functional measures were compared between survivors and controls with two sample t-tests or non-parametric equivalents. The percentages of survivors who performed below -1.5 and -2 SD of expected (compared to controls) were calculated to illustrate magnitude of functional loss.

Means for composite and subscale scores on the SF-36 were compared between survivors and controls with two sample t-tests. Percentages of survivors in social attainment categories were contrasted to controls with Chi-Square statistics. Associations between disease (tumor type, location, bone involvement) and treatment variables, health conditions and impaired performance (-1.5 SD) on physical measures were evaluated with multivariable logistic regression among survivors. Associations between impaired performance on physical measures and poor HRQOL were also evaluated with logistic regression. Variables with p-values > 0.10 in preliminary univariable models were retained for inclusion in multivariate models. Multicollinearity was evaluated to avoid over fitting. SAS version 9.3 (SAS Institute, Cary, NC) was used for analysis.

RESULTS

Characteristics of study participants

Of 328 extremity sarcoma survivors potentially eligible, 20 elected to complete a survey only, 13 were lost to follow-up, 25 were interested but had not yet completed a campus visit at the time of this analysis, and 61 declined participation. This report summarizes results of 209 (63.7%) participants with a campus visit, 206 of whom completed a functional assessment. Participants did not differ from non-participants by sex, race, diagnosis, or age at diagnosis. Characteristics of the study population are shown in Table 1. Median ages at evaluation were: bone sarcoma (BS), 38 (range, 21–65) years, soft tissue sarcoma (STS), 33 (range, 19–61) years, and controls, 33 (range, 19–51) years. BS survivors were more likely to be male and STS survivors more likely to be female. The most frequent BS histology was osteosarcoma; the most frequent STS histology was non-rhabdomyosarcoma soft tissue sarcoma. The most frequent tumor site was the lower extremity (81%).

Surgery was the primary method of local control for 84% of survivors; 43.9% with BS and 32.7% with STS had amputation for local control. Amputation was required as the result of local complication/relapse for an additional 13.4% of BS and 6.1% of STS survivors. Pulmonary metastases at diagnosis resulted in thoracotomies among 12 BS and 4 STS patients. An additional 27 participants had thoracotomy for relapsed pulmonary disease. Overall, the 206 participants had 783 surgical procedures; mean per patient 3.8 (95% CI: 3.4–4.3). Chest radiation was received by 5.8%, and limb radiation by 22.3% of patients. Nearly all BS, but less than half of STS were treated with anthracycline and alkylating containing regimens. Platinum was received by 46.5% of BS and 10.2% of STS survivors.

Health outcome data with potential impact on physical function are also shown in Table 1. Relative lean mass < -1.5 SD was observed in approximately 36% of BS and 43% of STS survivors. EF $< 50\%$ was present in 12% of BS and 2% of STS survivors. DLCO_{corr} $< 75\%$ was present in 57% of BS and 33% of STS survivors. Over 25% of survivors had sensory

and 25.2% motor neuropathy. Musculoskeletal complications were experienced by 78.2% of patients (mean rate per patient 1.9 (Range 0–8)). The most common long-term musculoskeletal complication was fracture associated with traumatic injury (28.8%), followed by prosthetic malfunction/complication (8.3%).

Physical performance, HRQOL, social roles

Table 2 demonstrates mean values (survivors and controls) and percentages of survivors with values 1.5 and 2.0 SD below age- and sex-specific expected values (using our control population) for physical performance and HRQOL. Severe deficits in performance on the six-minute-walk test, balance measures, and physical component summary and physical function subscale of the SF-36 were observed in over 25% of survivors. A substantial number of survivors (>15% when the expected rate is only 6.7%) also had severe limitations in strength, social functioning and activities of daily living. Survivors and controls had similar percentages for marriage (60.2 vs. 60.9%, $p=0.79$), independent living (75.7 vs. 72.8%, $p=0.99$), employment (70.9 vs. 75.7%, $p=0.14$), and college attendance (63.6 vs. 68.5%, $p=0.06$).

Treatment and physical performance

Table 3 shows the results of multivariable models examining associations between treatment and poor physical performance among survivors. After adjusting for other treatment exposures, tumor location in the lower extremity and amputation were the only factors associated with any performance outcomes, impacting balance and cardiopulmonary fitness.

Chronic conditions and physical performance

Table 4 shows the results of multivariable models examining associations between specific chronic conditions, number of musculoskeletal complications, and poor physical performance among survivors. Relative low lean muscle mass was associated with quadriceps and ankle weakness and with balance impairment. EF <50% was associated with impaired balance and quadriceps weakness, DLCO_{corr} <75% was associated with impaired flexibility. Motor neuropathy was associated with impaired flexibility, quadriceps and ankle weakness, impaired fitness and limited activities of daily living. The presence of two or more musculoskeletal complications was associated with impaired balance, and amputation was associated with impaired balance and impaired fitness. Sensory neuropathy was not associated with any of the physical performance outcomes.

Physical performance and HRQOL

Table 5 shows the results of multivariable models examining associations between physical performance measures and scoring <40 on the summary and subscales of the SF-36. Impaired fitness and limited activities of daily living were associated with a suboptimal outcome on the physical component summary of the SF-36; fitness impairment was also associated with scoring < 40 on the role physical subscale of the SF-36. Social functioning was not impacted by any of the physical performance impairments.

DISCUSSION

Prior investigations have relied on self-report or clinician based observations to describe long-term functional outcomes and HRQOL in adult survivors of childhood extremity sarcomas [6,11,30,31]. In this study, we provide results of an extensive clinical assessment of long-term musculoskeletal sarcomas of the extremities among survivors evaluated decades following treatment. Nearly 80% of extremity sarcoma survivors in this cohort treated 1962–2004 experienced musculoskeletal complications after initial local control. These complications required subsequent surgical intervention, including eventual amputation among some initially treated with limb sparing surgery. We also document significant rates of other adverse health outcomes in this population, including impaired cardiac and pulmonary function, low lean mass, peripheral neuropathy, muscle weakness, poor balance, impaired fitness, and limitations in activities of daily living. In addition, we observed that performance limitations are associated with reduced HRQOL in physical domains. Despite these impairments, survivors were as likely as controls to be married, live independently, be employed, and attend college.

Our study indicates a higher prevalence of musculoskeletal complications among extremity sarcoma survivors than previously reported. For example, Hamilton et al. [32] reviewed progress notes of pediatric Ewing sarcoma survivors (median follow-up 13.5 years) treated 1960–2005 and reported that 50% of 64 patients who survived at least five years had long-term musculoskeletal abnormalities. Tan et al. [33] reported post-operative complications in 35% of 120 patients with osteosarcoma (mean follow-up 56.8 months) treated 1998–2008. These included infection, prosthetic loosening, fracture, and patellar tendon rupture. Mavrogenis et al [34] evaluated outcomes (median follow-up 67 month) among 42 patients with osteosarcoma in the distal tibia treated 1985–2010, reporting complications among 26% with limb sparing procedures and 5% with amputation. Our prevalence is more consistent with data from CCSS that reported a hazard ratio of 2.8 (95% CI 1.3 to 5.9) for grade 3–5 musculoskeletal chronic conditions when comparing survivors (total N=5,604, sarcoma N=1,342) 35+ years of age to siblings [35]. Like CCSS, our study included survivors with longer follow-up (median 25 years) and some survivors treated before 1980. Results emphasize the need for continuing orthopedic follow-up among extremity sarcoma survivors as they age.

Increased risk for cardiac and pulmonary conditions [7,8,11,36], neuropathy [37], and low lean muscle mass [38] in long-term pediatric extremity sarcoma survivors have been previously reported in large cohorts. However, only small studies have reported specific, objectively measured physical performance, and few report associations between chronic health conditions and physical performance, or between physical performance and HRQOL. In a study that included 30 sarcoma survivors aged 35±10 years, Gerber et al. [39] documented impaired range of motion in 67%, reduced gait velocity in 42%, and substantial problems with activities of daily living in 44%. As in our study, these authors observed that lower extremity tumor location was associated with impaired physical performance, and that suboptimal performance on a walking test was associated with worse scores on both measured and self-report of daily activity. Data from a younger cohort (N=68, ages 6–26

years) of patients with sarcoma at least one year post limb sparing surgery also described problems with joint range of motion and mobility (walking, stair climbing) [40].

Our data extends the results of these studies by identifying apparent musculoskeletal and other specific chronic health conditions that could be addressed as part of clinical/rehabilitative care to improve physical performance. Data suggests that structured exercise for pediatric sarcoma survivors with subclinical cardiomyopathy is feasible and safe [41], and that intense exercise post-pneumonectomy improves lung function, strength, and fitness [42]. Evidence also exists to support resistance training to improve lean muscle mass [43], and vestibular rehabilitation to improve balance [44].

Our finding that survivors of childhood musculoskeletal sarcomas of the extremities report poor HRQOL in physical but not mental or emotional domains is consistent with others [45]. Although some attribute this to potential alteration in expectations among individuals who have become accustomed to disability over time, in a much younger cohort (N=82, ages 8–25 years) of bone sarcoma survivors, Bekkering et al. [45] reported impaired HRQOL only in physical domains when comparing survivors to controls. Importantly, survivors of sarcoma who participated in our study did not have social outcomes different from controls, nor did they indicate that physical performance impacted social function.

There are limitations that should be considered when evaluating results. First, therapy for extremity musculoskeletal sarcomas has changed from 1962 to 2004, the period of diagnosis for our participants. Data from older survivors may not apply to children treated today with fewer amputations, improved surgical techniques and better hospital care. Second, this was a cross sectional analysis, concomitant evaluation of physical performance measures and HRQOL does not allow interpretation of a temporal association between these outcomes. Although we found no differences among survivors by diagnosis, sex, race/ethnicity, or age, it is possible that survivors with more or less disability, either unable to travel, or more likely to be too busy to return to the institution, were less likely to participate, which would bias our results. Finally, although our population is large and well characterized, it is heterogeneous in terms of tumor type and location, making it difficult to draw conclusions about specific sub-populations.

CONCLUSIONS

Long-term survivors of extremity sarcomas experience complications and have low scores on physical performance measures. Low lean muscle mass, impaired cardiac and pulmonary function, and neuropathy contribute to their poor performance. Follow-up for extremity sarcoma survivors should include assessment of need for further orthopedic care and rehabilitation to address cardiopulmonary and musculoskeletal health.

Acknowledgments

Funding: This work was supported by Grant CA 21765 from the National Cancer Institute and ALSAC.

References

1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. *Cancer*. 2009; 115:1531–1543. [PubMed: 19197972]
2. Pappo AS, Pratt CB. Soft tissue sarcomas in children. *Cancer Treat Res*. 1997; 91:205–222. [PubMed: 9286498]
3. Howlader, N., Noone, AM., Krapcho, M., Garshell, J., Miller, D., Altekruse, SF., et al. SEER Cancer Statistics Review, 1975–2011. National Cancer Institute; Bethesda, MD: Apr. 2014 http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site
4. Denbo JW, Zhu L, Srivastava D, Stokes DC, Srinivasan S, Hudson MM, et al. Long-term pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude lifetime cohort study. *J Am Coll Surg*. 2014; 219:265–271. [PubMed: 24795268]
5. Green DM, Kun LE, Matthay KK, Meadows AT, Meyer WH, Meyers PA, et al. Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. *Pediatr Blood Cancer*. 2013; 60:1083–1094. [PubMed: 23418018]
6. Punyko JA, Mertens AC, Gurney JG, Yasui Y, Donaldson SS, Rodeberg DA, et al. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study. *Pediatr Blood Cancer*. 2005; 44:643–653. [PubMed: 15700252]
7. Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. *Cancer*. 2011; 117:625–634. [PubMed: 20922787]
8. Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. *Cancer*. 2002; 95:2431–2441. [PubMed: 12436452]
9. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Clin Oncol*. 2010; 28:332–339. [PubMed: 19949008]
10. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. *J Clin Oncol*. 2009; 27:2677–2685. [PubMed: 19364965]
11. Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. *J Natl Cancer Inst*. 2010; 102:1272–1283. [PubMed: 20656964]
12. Marina N, Hudson MM, Jones KE, Mulrooney DA, Avedian R, Donaldson SS, et al. Changes in health status among aging survivors of pediatric upper and lower extremity sarcoma: a report from the childhood cancer survivor study. *Arch Phys Med Rehabil*. 2013; 94:1062–1073. [PubMed: 23380347]
13. Hudson MM, Ness KK, Nolan VG, Armstrong GT, Green DM, Morris EB, et al. Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort study. *Pediatr Blood Cancer*. 2011; 56:825–836. [PubMed: 21370418]
14. Ojha RP, Oancea SC, Ness KK, et al. Assessment of potential bias from non-participation in a dynamic clinical cohort of long-term childhood cancer survivors: results from the St. Jude Lifetime Cohort Study. *Pediatr Blood Cancer*. 2013; 60:856–864. [PubMed: 23024097]
15. Mayorga-Vega D, Merino-Marban R, Viciano J. Criterion-Related Validity of Sit-and-Reach Tests for Estimating Hamstring and Lumbar Extensibility: a Meta-Analysis. *J Sports Sci Med*. 2014; 13:1–14. [PubMed: 24570599]
16. Baggett BD, Young G. Ankle joint dorsiflexion. Establishment of a normal range. *J Am Podiatr Med Assoc*. 1993; 83:251–254. [PubMed: 8135911]
17. Moseley AM, Crosbie J, Adams R. Normative data for passive ankle plantarflexion--dorsiflexion flexibility. *Clin Biomech (Bristol, Avon)*. 2001; 16:514–521.

18. Cohen H, Heaton LG, Congdon SL, Jenkins HA. Changes in sensory organization test scores with age. *Age Ageing*. 1996; 25:39–44. [PubMed: 8670527]
19. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and pinch strength evaluations. *J Hand Surg Am*. 1984; 9:222–226. [PubMed: 6715829]
20. Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. *Arch Phys Med Rehabil*. 1985; 66:69–74. [PubMed: 3970660]
21. Danneskiold-Samsoe B, Bartels EM, Bulow PM, Lund H, Stockmarr A, Holm CC, et al. Isokinetic and isometric muscle strength in a healthy population with special reference to age and gender. *Acta Physiol (Oxf)*. 2009; 197(Suppl 673):1–68.
22. Drouin JM, Valovich McLeod TC, Shultz SJ, Gansneder BM, Perrin DH. Reliability and validity of the Biodex system 3 pro isokinetic dynamometer velocity, torque and position measurements. *Eur J Appl Physiol*. 2004; 91:22–29. [PubMed: 14508689]
23. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002; 166:111–117. [PubMed: 12091180]
24. Reuben DB, Siu AL. An objective measure of physical function of elderly outpatients. The Physical Performance Test. *J Am Geriatr Soc*. 1990; 38:1105–1112. [PubMed: 2229864]
25. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992; 30:473–483. [PubMed: 1593914]
26. Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. *PloS one*. 2009; 4:e7038. [PubMed: 19753111]
27. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013; 62:e147–e239. [PubMed: 23747642]
28. Neas LM, Schwartz J. The determinants of pulmonary diffusing capacity in a national sample of U.S. adults. *Am J Respir Crit Care Med*. 1996; 153:656–664. [PubMed: 8564114]
29. U.S. Department of Health and Human Services-National Institutes of Health-National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2010.
30. Nagarajan R, Clohisey DR, Neglia JP, Yasui Y, Mitby PA, Sklar C, et al. Function and quality-of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing's sarcoma: the Childhood Cancer Survivor Study. *Br J Cancer*. 2004; 91:1858–1865. [PubMed: 15534610]
31. Stish BJ, Ahmed SK, Rose PS, Arndt CA, Laack NN. Patient-Reported Functional and Quality of Life Outcomes in a Large Cohort of Long-Term Survivors of Ewing Sarcoma. *Pediatr Blood Cancer*. 2015; 62:2189–96. [PubMed: 26275239]
32. Hamilton SN, Carlson R, Hasan H, Rassekh SR, Goddard K. Long-term Outcomes and Complications in Pediatric Ewing Sarcoma. *Am J Clin Oncol*. 2015 Jan 16.
33. Tan PX, Yong BC, Wang J, Huang G, Yin JQ, Zou CY, et al. Analysis of the efficacy and prognosis of limb-salvage surgery for osteosarcoma around the knee. *Eur J Surg Oncol*. 2012; 38:1171–1177. [PubMed: 22809860]
34. Mavrogenis AF, Abati CN, Romagnoli C, Ruggieri P. Similar survival but better function for patients after limb salvage versus amputation for distal tibia osteosarcoma. *Clin Orthop Relat Res*. 2012; 470:1735–48. [PubMed: 22270466]
35. Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. *J Clin Oncol*. 2014; 32:1218–1227. [PubMed: 24638000]
36. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. *BMJ*. 2009; 339:b4606. [PubMed: 19996459]
37. Ness KK, Jones KE, Smith WA, Spunt SL, Wilson CL, Armstrong GT, et al. Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. *Arch Phys Med Rehabil*. 2013; 94:1451–1457. [PubMed: 23537607]

38. Ness KK, Krull KR, Jones KE, Mulrooney DA, Armstrong GT, Green DM, et al. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. *J Clin Oncol*. 2013; 31:4496–4503. [PubMed: 24248696]
39. Gerber LH, Hoffman K, Chaudhry U, Augustine E, Parks R, Bernad M, et al. Functional outcomes and life satisfaction in long-term survivors of pediatric sarcomas. *Arch Phys Med Rehabil*. 2006; 87:1611–1617. [PubMed: 17141641]
40. Marchese VG, Spearing E, Callaway L, Rai SN, Zhang L, Hinds PS, et al. Relationships among range of motion, functional mobility, and quality of life in children and adolescents after limb-sparing surgery for lower-extremity sarcoma. *Pediatr Phys Ther*. 2006; 18:238–244. [PubMed: 17108796]
41. Smith WA, Ness KK, Joshi V, Hudson MM, Robison LL, Green DM. Exercise training in childhood cancer survivors with subclinical cardiomyopathy who were treated with anthracyclines. *Pediatr Blood Cancer*. 2013 Nov 6.
42. Edvardsen E, Skjøsberg OH, Holme I, Nordsletten L, Borchsenius F, Anderssen SA. High-intensity training following lung cancer surgery: a randomised controlled trial. *Thorax*. 2015; 70:244–250. [PubMed: 25323620]
43. Guimaraes-Ferreira L, Cholewa JM, Naimo MA, Zhi XI, Magagnin D, de Sá RB, et al. Synergistic effects of resistance training and protein intake: Practical aspects. *Nutrition*. 2014; 30:1097–103. [PubMed: 24751198]
44. Vereeck L, Wuyts FL, Truijen S, De Valck C, Van de Heyning PH. The effect of early customized vestibular rehabilitation on balance after acoustic neuroma resection. *Clin Rehabil*. 2008; 22:698–713. [PubMed: 18678570]
45. Bekkering WP, Vliet Vlieland TP, Koopman HM, Schaap GR, Beishuizen A, Anninga JK, et al. A prospective study on quality of life and functional outcome in children and adolescents after malignant bone tumor surgery. *Pediatr Blood Cancer*. 2012; 58:978–985. [PubMed: 21990185]

Table 1

Characteristics of the study population

	Bone sarcoma (n=157)	Soft-tissue sarcoma (n=49)	Comparison group (n=206)
Age at diagnosis			
Mean (SD)	13.1 (4.2)	11.4 (5.2)	
Median (Range)	13.7 (2.9–23.6)	12.0 (0–20.9)	
Age at assessment			
Mean (SD)	38.0 (9.7)	34.7 (9.1)	33.1 (7.2)
Median (Range)	38.2 (21.3–65.1)	33.4 (19.4–61.5)	33.3 (19.3–50.8)
Sex			
Female	68 (43.3)	30 (61.2)	98 (47.6)
Male	89 (56.7)	19 (38.8)	108 (52.4)
Race			
Non-Hispanic White	129 (82.2)	37 (75.5)	168 (81.5)
Non-Hispanic Black	23 (14.6)	12 (24.5)	35 (17.0)
Other	5 (3.2)	-	3 (1.5)
Tumor histology			
Osteosarcoma	105 (66.9)	-	
Ewing sarcoma	52 (33.1)	-	
Rhabdomyosarcoma	-	9 (18.4)	
Other soft-tissue	-	40 (81.6)	
Tumor location *			
Upper extremity	21 (13.4)	18 (36.7)	
Lower extremity	137 (87.3)	31 (63.3)	
Surgery			
Local Control[#]	129 (82.8)	44 (89.8)	
Limb sparing	52 (33.1)	7 (14.3)	
Excision of mass	9 (5.7)	30 (68.2)	
Hip disarticulation	8 (5.1)	2 (4.6)	
Above knee amputation	48 (30.6)	2 (4.6)	
Below knee amputation	3 (1.9)	-	
Forequarter amputation	6 (3.8)	1 (2.3)	
Above elbow amputation	2 (1.3)	-	
Below elbow amputation	2 (1.3)	2 (4.6)	
Metastasis	13 (8.3)	5 (10.2)	
Thoracotomy	12 (7.6)	4 (80.0)	
Excision of mass	1 (0.7)	-	
Complications[#]	56 (33.1)	11 (28.6)	
New limb sparing	4 (2.5)	-	

	Bone sarcoma (n=157)	Soft-tissue sarcoma (n=49)	Comparison group (n=206)
Limb sparing revisions	23 (14.6)	2 (4.1)	
Hip disarticulation	1 (0.7)	-	
Above knee amputation	11 (7.0)	-	
Below knee amputation	2 (1.3)	1 (2.0)	
Other musculoskeletal repair	11 (7.0)	8 (16.3)	
Relapse[#]	29 (18.5)	11 (22.4)	
New limb sparing	-	2 (4.1)	
Limb sparing revisions	4 (2.5)	-	
Excision of mass	-	3 (6.1)	
Hip disarticulation	3 (1.9)	-	
Above knee amputation	2 (1.3)	1 (2.0)	
Below knee amputation	1 (0.7)	-	
Above elbow amputation	1 (0.7)	-	
Below elbow amputation		1 (2.0)	
Thoracotomy	20 (12.7)	7 (14.3)	
Radiation			
Chest (N)	6	6	
Mean maximal dose (SD) Gy	39.0 (14.4)	43.8 (17.3)	
Median maximal dose (SD) Gy	37. (16.–55.0)	51.9 (12.0–56.0)	
Limb (N)	26	20	
Mean maximal dose (SD) Gy	47.2 (12.6)	50.8 (9.3)	
Median maximal dose (SD) Gy	46.0 (35.0–82.0)	49.7 (30.6–74.2)	
Chemotherapy			
Anthracycline (N)	146	19	
Mean total dose (SD) mg/m ²	366.8 (73.5)	285.8 (142.1)	
Median total dose (Range) mg/m ²	376.0 (129.5–560.7)	295.8 (60.1–689.5)	
Alkylating agents (N)	150	24	
Mean total dose ^{\$} (SD) mg/m ²	11747.7 (7569.5)	11606.9 (5362.0)	
Median total dose ^{\$} (Range) mg/m ²	9739.3 (575.0–36964.7)	11807.3 (1133.3–21904.2)	
Platinum (N)	73	5	
Mean total dose ^{\$} (SD) mg/m ²	1700.1 (1607.6)	884.4 (1258.9)	
Median total dose ^{\$} (Range) mg/m ²	421.2 (100.0–5966.4)	292.3 (182.0–2771.2)	
Health outcomes			
Relative lean mass < -1.5 SD	56 (35.7)	21 (42.9)	
Ejection fraction < 50%	18 (12.1)	1 (2.0)	
DLCO < 75%	90 (57.3)	16 (32.7)	
Sensory neuropathy 2	44 (28.0)	13 (26.5)	
Motor neuropathy 2	38 (24.2)	14 (28.6)	

	Bone sarcoma (n=157)	Soft-tissue sarcoma (n=49)	Comparison group (n=206)
Musculoskeletal complications			
Any (N)	124 (79.0)	37 (75.5)	
Median (Range)	2 (1–8)	2 (1–7)	
Type of complication			
Fracture with traumatic injury	96	19	
Prosthetic malfunction	31	2	
Intervertebral disc disorder	17	11	
Arthropathy, monoarticular	20	7	
Scoliosis	18	9	
Pathological fracture with tumor	22	3	
Benign bone lesion/cysts	14	7	
Leg/arm length discrepancy	14	8	
Low bone mineral density	15	2	
Exostosis	6	5	
Arthropathy, polyarticular	8	3	
Contracture	9	1	
Other	33	19	

* One person with two tumors (one upper, one lower extremity);

Individual categories are not mutually exclusive, participants may have had more than one procedure for complication of relapse;

\$ Cyclophosphamide equivalents⁶⁴.

SD=standard deviations, Gy=gray, mg=milligram, %=percent

Physical performance and health related quality of life

Table 2

	Comparison group		Survivors		p-value	Survivors with severe impairment			
	Mean	SD	Mean	SD		< -1.5 SD		< -2.0 SD	
						N	%	N	%
Flexibility									
Active dorsiflexion (degrees)	11.1	6.6	8.2	8.4	<0.001	39	19.0	17	8.3
Active plantarflexion (degrees)	54.4	7.6	54.0	10.4	0.64	19	9.3	7	3.4
Sit and reach test (cm)	25.9	9.1	22.0	10.0	<0.001	37	18.1	20	9.8
Balance									
Composite (%)	79.4	6.8	76.7	10.8	0.01	66	32.5	56	27.6
Vestibular (%)	74.2	11.6	69.1	22.0	0.01	55	27.1	54	26.6
Strength									
Grip (kg)	42.2	12.5	41.9	13.5	0.79	12	5.8	1	0.5
Knee extension									
60 degrees/second	169.8	59.2	153.9	55.2	0.01	38	18.6	29	14.2
180 degrees/second	107.1	40.9	96.5	39.9	0.01	38	18.6	31	15.2
300 degrees/second	76.1	31.5	69.6	27.5	0.03	32	15.7	28	13.7
Dorsiflexion									
60 degrees/second	20.2	8.7	18.1	9.0	0.03	41	20.1	33	16.2
90 degrees/second	17.1	6.8	15.6	7.1	0.03	40	19.6	33	16.2
Plantarflexion									
60 degrees/second	56.8	25.2	67.3	31.7	0.001	39	19.1	34	16.7
90 degrees/second	49.2	22.8	53.5	25.4	0.09	39	19.1	33	16.2
Fitness									
Meters walked 6-minutes	610.4	94.7	525.0	109.3	<0.001	81	39.5	60	29.3
PCI beats/meter	0.5	0.2	0.6	0.2	<0.001	36	17.8	29	14.4
Activities of daily living									
Physical performance test	23.4	1.0	22.6	2.0	<0.001	36	17.5	36	17.5
Health related quality of life									

	Comparison group		Survivors		p-value	Survivors with severe impairment < -1.5 SD		Survivors with severe impairment < -2.0 SD	
	Mean	SD	Mean	SD		N	%	N	%
Physical component summary	54.6	6.9	46.8	10.8	<0.001	69	35.9	53	27.6
Mental component summary	50.1	10.0	50.0	11.4	0.92	21	10.9	17	8.9
General health	51.7	9.1	46.9	10.6	<0.001	36	18.2	13	6.6
Physical function	53.9	6.9	45.5	11.0	<0.001	78	39.2	54	27.1
Role-physical	54.1	7.0	49.2	10.4	<0.001	44	22.6	40	20.5
Bodily pain	53.6	8.8	47.2	11.2	<0.001	49	24.5	29	14.5
Vitality	52.8	9.6	48.9	10.7	<0.001	30	15.1	23	11.6
Social functioning	51.5	8.0	48.0	10.9	<0.001	35	17.5	35	17.5
Role-emotional	51.1	9.2	49.4	10.9	0.11	33	16.8	26	13.3
Mental health	50.4	10.1	48.8	10.3	0.11	23	11.6	7	3.5

cm=centimeter, kg=kilogram, PCI=percutaneous coronary intervention, SD=standard deviation, %=percent

Table 3

Association between treatments related risk factors and physical performance measures from multivariable models

	Any flexibility impairment (N=75)				Balance impairment (N=68)				Quadriceps strength impairment (N=43)				Ankle strength impairment (N=52)				Finex impairment (N=81)				Limited activities of daily living (N=36)			
	N (row %)	OR	95% CI	P-value	N (row %)	OR	95% CI	P-value	N (row %)	OR	95% CI	P-value	N (row %)	OR	95% CI	P-value	N (row %)	OR	95% CI	P-value	N (row %)	OR	95% CI	P-value
Tumor location																								
Upper extremity	14 (35.9)				4 (10.5)				4 (10.3)								4 (10.3)							
Lower extremity	61 (36.8)				64 (38.8)	4.36	1.37–13.73	0.01	39 (23.6)	2.56	0.84–7.82	0.10	48 (29.1)	3.64	1.22–10.88	0.02	77 (46.4)	8.23	2.54–26.67	0.0004	33 (19.8)	2.34	0.65–8.38	0.19
Final surgical outcome																								
Excision or biopsy only	26 (40.6)				11 (17.5)	1.00			13 (20.6)				17 (27.0)				9 (14.3)	1.00			8 (12.5)	1.00		
Limb sparing	20 (46.5)				8 (19.5)	0.96	0.34–2.73	0.94	6 (14.0)				9 (20.9)				9 (20.9)	1.50	0.32–3.48	0.94	4 (9.3)	0.36	0.09–1.36	0.13
Below knee/elbow amputation *	3 (25.0)				3 (25.0)	2.14	0.45–10.12	0.34	0 (0)				24 (27.9)				62 (76.5)	8.07	3.06–21.27	<0.0001	24 (66.7)	1.06	0.40–2.80	0.91
Above knee/elbow amputation *	26 (30.2)				46 (52.9)	4.35	1.90–9.94	0.001	24 (55.8)				2 (16.7)				1 (1.2)				0 (0)			
Thoracotomy																								
No	55 (33.5)	1.00			50 (30.7)	1.00			34 (20.9)				40 (24.5)				60 (36.6)	1.00			27 (16.4)			
Yes	20 (48.8)	1.68	0.82–3.42	0.15	18 (45.0)	1.42	0.65–3.07	0.38	9 (22.0)				12 (29.3)				21 (51.2)	1.37	0.57–3.29	0.49	9 (22.0)			
Limb reduction																								
No	58 (36.5)				57 (35.6)				39 (24.5)	1.00			40 (25.2)				74 (46.3)	1.00			34 (21.3)	1.00		
Yes	17 (37.0)				11 (25.6)				4 (8.9)	0.32	0.11–0.97	0.04	12 (26.7)				7 (15.6)	0.51	0.18–1.46	0.21	2 (4.4)	0.17	0.04–0.79	0.02
Chest radiation																								
No	67 (34.7)	1.00		0.06	65 (33.9)				41 (21.4)				50 (26.0)				78 (40.4)				35 (18.0)			
Yes	8 (66.7)	3.29	0.93–11.64		3 (27.3)				2 (16.7)				2 (16.7)				3 (25.0)				1 (8.3)			
Antiher asyclyline																								
No	12 (29.3)				9 (22.0)	1.00			8 (19.5)				13 (31.7)				12 (29.3)				6 (14.6)			
Yes	63 (38.4)				59 (36.4)	1.11	0.45–2.76	0.83	35 (21.5)				39 (23.9)				69 (42.1)				30 (18.2)			
Anti/raising agent																								
No	8 (25.0)				5 (15.6)				4 (12.5)				7 (21.9)				7 (21.9)				4 (12.5)			
Yes	67 (38.7)				63 (36.8)				39 (22.7)				45 (26.2)				74 (42.8)				32 (18.4)			
Platinum																								
No	44 (34.7)				36 (28.6)				22 (17.5)				29 (23.0)				42 (33.1)	1.00			21 (16.4)			
Yes	31 (39.7)				32 (41.6)				21 (26.9)				23 (29.5)				39 (50.0)	1.08	0.48–2.46	0.85	15 (19.2)			

* Includes hemipelvectomy/hip disarticulation or forequarter amputation. All models adjusted for age at diagnosis.

** Amputation categories combined for multiple variable analyses.

%=percent, CI=confidence interval. Please note: in the table, the OR only calculated for the variables who had p-value 0.1 from univariate analyses

Table 4
Association between health conditions, musculoskeletal complications and physical performance from multivariable models

	Any flexibility impairment (N=75)					Balance impairment (N=66)					Quadriceps strength impairment (N=43)					Ankle strength impairment (N=52)					Fitness impairment (N=40)					Limited activities of daily living (N=36)				
	N	Row	OR	95% CI	P-value	N	Row	OR	95% CI	P-value	N	Row	OR	95% CI	P-value	N	Row	OR	95% CI	P-value	N	Row	OR	95% CI	P-value	N	Row	OR	95% CI	P-value
Relative lean mass < -1.5 SD																														
No	49	38.3	1.00			37	29.1	1.00			18	14.1	1.00			2	18.	1.0			4	34.9	1.0		2	17.1	1.00			
Yes	26	33.8	0.58	0.29–1.15	0.12	31	40.8	2.03	1.03–4.02	0.04	25	32.9	3.16	1.47–6.80	0.003	2	38.	2.9	1.46–5.80	0.002	3	47.4	1.7	0.85–3.61	0.13	1	18.2	0.98	0.43–2.23	0.96
Ejection fraction < 50%																														
No	69	37.3	1.00			55	30.1	1.00			35	19.0	1.00			4	24.	1.0			7	37.8	1.0		2	15.6	1.00			
Yes	6	30.0	0.65	0.21–2.01	0.45	13	65.0	3.04	1.02–9.01	0.04	8	40.0	3.40	1.07–10.81	0.04	7	35.	2.0	0.66–6.27	0.21	1	55.0	0.7	0.23–2.46	0.65	7	35.0	2.32	0.74–7.23	0.15
DLCO < 75%																														
No	31	31.3	1.00			32	32.3	1.00			20	20.4	1.00			2	27.	1.0			3	36.4	1.0		1	11.0	1.00			
Yes	44	41.5	2.77	1.39–5.54	0.004	36	34.6	0.61	0.30–1.22	0.16	23	21.7	1.05	0.47–2.32	0.91	2	23.	0.7	0.36–1.49	0.39	4	42.5	0.7	0.36–1.61	0.48	2	23.6	2.36	1.00–5.58	0.05
Sensory neuropathy 2																														
No	48	32.4	1.00			49	33.6	1.00			29	19.7	1.00			3	24.	1.0			5	37.8	1.0		2	14.8	1.00			
Yes	27	47.4	1.29	0.64–2.62	0.48	19	33.3	0.92	0.43–1.98	0.84	14	24.6	0.84	0.36–1.98	0.69	1	28.	0.8	0.38–1.83	0.66	2	43.9	0.9	0.44–2.25	0.98	1	24.6	1.38	0.58–3.27	0.47
Motor neuropathy 2																														
No	43	28.1	1.00			45	29.8	1.00			20	13.2	1.00			2	19.	1.0			4	30.1	1.0		1	12.3	1.00			
Yes	32	61.5	5.81	2.70–12.52	<0.0001	23	44.2	1.54	0.72–3.28	0.26	23	44.2	5.34	2.37–12.02	<0.0001	2	44.	3.1	1.51–6.73	0.002	3	67.3	6.1	2.59–14.59	<0.000	1	32.7	3.40	1.43–8.09	0.006
Number of musculoskeletal complications																														
None	12	27.3	1.00			11	25.0	1.00			10	22.7	1.00			1	29.	1.0			1	35.6	1.0		1	24.4	1.00			
One	20	39.2	2.11	0.80–5.54	0.13	15	29.4	1.52	0.54–4.24	0.43	10	19.6	0.96	0.31–2.97	0.94	1	21.	0.6	0.23–1.74	0.37	1	37.3	1.7	0.59–5.04	0.32	5	9.8	0.26	0.08–0.93	0.04
Two+	43	39.1	1.48	0.64–3.42	0.36	42	38.9	2.90	1.18–7.17	0.02	23	21.1	0.76	0.29–2.02	0.59	2	25.	0.6	0.30–1.63	0.40	4	42.2	2.4	0.95–6.33	0.06	2	18.2	0.62	0.24–1.56	0.31
Amputation																														
No	46	43.0	1.00			19	18.3	1.00			19	17.9	1.00			2	24.	1.0			1	17.0	1.0		1	11.2	1.00			
Yes	29	29.6	0.37	0.15–0.76	0.007	49	49.5	5.33	2.53–11.24	<0.0001	24	24.5	1.08	0.47–2.49	0.85	2	26.	0.9	0.43–1.92	0.81	6	63.6	14.	6.32–34.53	<0.000	2	24.2	1.51	0.62–3.64	0.36

Models adjusted for age at diagnosis

%=percent, CI=confidence interval, SD=standard deviation, +=plus,

Associations between poor physical performance and HRQOL from multivariable models

Table 5

	PCS < 40 (N=45)					Role physical < 40 (N=40)					Social functioning < 40 (N=35)				
	N	Row %	OR	95% CI	P-value	N	Row %	OR	95% CI	P-value	N	Row	OR	95% CI	P-value
Flexibility impairment															
No	22	17.7	1.00			20	16.0	1.00			20	15.8	1.00		
Yes	23	34.3	1.92	0.86–4.26	0.11	20	29.0	1.45	0.64–3.28	0.37	15	20.8	1.16	0.52–2.57	0.71
Balance impairment															
No	27	20.6	1.00			22	16.7	1.00			23	17.2	1.00		
Yes	18	30.5	0.55	0.22–1.37	0.20	17	28.3	0.75	0.31–1.85	0.54	12	19.1	0.63	0.25–1.58	0.33
Quadriceps strength impairment															
No	28	18.3	1.00			24	15.5	1.00			23	14.7	1.00		
Yes	17	46.0	1.85	0.49–6.99	0.37	16	42.1	1.99	0.54–7.27	0.30	12	29.3	1.64	0.46–5.86	0.45
Ankle strength impairment															
No	28	19.2	1.00			24	16.2	1.00			22	14.7	1.00		
Yes	17	38.6	0.84	0.23–3.00	0.79	16	35.6	1.03	0.30–3.56	0.96	13	27.1	1.32	0.42–4.19	0.64
Fitness impairment															
No	13	10.9	1.00			13	10.7	1.00			16	13.1	1.00		
Yes	32	44.4	4.83	1.95–11.99	0.001	27	37.0	3.34	1.33–8.43	0.01	19	24.7	1.74	0.69–4.38	0.24
Limited activities of daily living															
No	27	16.9	1.00			25	15.5	1.00			26	15.8	1.00		
Yes	18	56.3	2.99	1.19–7.51	0.02	15	44.1	2.14	0.86–5.30	0.10	9	25.7	1.21	0.46–3.18	0.70

Models adjusted for age at diagnosis

% = percent, HRQOL = health related quality of life